The recognition of genital chlamydial infection as an important public health problem was made first by the recognition of its role in acute clinical syndromes, as well as in serious reproductive and ocular complications, and secondly by our awareness of its prevalence when diagnostic tests became widely accessible. The recent availability of effective single dose oral antimicrobial therapy and sensitive molecular amplification tests that allow the use of noninvasive specimens for diagnosis and screening is expected to have a major impact in reducing the prevalence of disease in the next decade. Clinical manifestations associated with Chlamydia pneumoniae infection continue to emerge beyond respiratory illness. In particular, its association with atherosclerosis deserves further investigation. Chlamydia pecorum, a pathogen of ruminants, was recently recognized as a new species. The continued application of molecular techniques will likely elucidate an expanding role for chlamydiae in human and animal diseases, delineate the phylogenetic relationships among chlamydial species and within the eubacteria domain, and provide tools for detection and control of chlamydial infections. |
Chlamydiae are obligate intracellular bacteria that grow in eukaryotic cells and cause a wide spectrum of human disease (Table). Species were grouped according to their biologic and biochemical properties and a greater than 95% homology in their 16s ribosomal RNA sequences (1). Molecular analyses led to the reclassification of some Chlamydia psittaci strains as Chlamydia pneumoniae, a human pathogen, and Chlamydia pecorum, a pathogen of ruminants. Given the diverse host range of C. psittaci strains, more reclassification within this species may be likely.
Species | Acute Diseases | Sequelae/Chronic Diseases |
C. trachomatis | ||
Serovars A-C | conjunctivitis | trachoma |
Serovars D-K | urethritis | proctitis, epididymo-orchitis, Reiter's Syndrome |
cervicitis | pelvic inflammatory disease, ectopic pregnancy, tubal infertility, Fitz-Hugh Curtis Syndrome | |
ophthalmia neonatorum | ||
neonatal pneumonia | ||
LGV serovars | lymphogranuloma venereum | |
C. pneumoniae | pharyngitis | ?cardiovascular disease |
sinusitis | ?asthma | |
bronchitis | ||
community-acquired pneumonia | ||
C. psittaci | ||
parrot | atypical pneumonia | |
canaries | hepatic and renal | |
pigeons | dysfunction | |
turkeys | endocarditis | |
ducks | ||
chickens | ||
cats | conjunctivitis | |
ewes | abortion | |
The oldest reported disease associated with C. trachomatis infection is trachoma, a sequela of ocular infection. This disease was described in China and in the Ebers papyrus in Egypt thousands of years ago and continues to be a major cause of preventable blindness, with an estimated 500 million cases of active trachoma worldwide (seven million include blindness from conjunctival scarring and eyelid deformities [2]). In the last two decades, genital chlamydial infection has been identified as a major public health problem because of the recognition that chlamydial infection is associated with disease syndromes such as nongonococcal urethritis, mucopurulent cervicitis, pelvic inflammatory disease (PID), ectopic pregnancy, and tubal infertility. The World Health Organization estimated 89 million new cases of genital chlamydial infections worldwide in 1995 (3). In the United States, each year an estimated four million new cases occur and 50,000 women become infertile as a result of infection (4).
C. psittaci infection, acquired through respiratory droplet transmission of
chlamydiae from infected birds, has been considered for many years an occupational hazard for
employees of pet shops and poultry processing plants (5). Sources of human
C. psittaci infection other than infected birds have been identified and may
C. pneumoniae is a human pathogen recognized as an important cause of respiratory illness (8). Approximately 40% to 60% of adult populations around the world have antibodies to C. pneumoniae, which suggests that the infection is extraordinarily prevalent, and reinfection is common. Current interest centers on the emerging role of C. pneumoniae infection in the pathogenesis of atherosclerosis and asthma.
Chlamydiae are considered energy parasites because they lack the enzymes of the
electron transport chain and thus require adenosine triphosphate (ATP) and nutrient
Control programs emphasizing early diagnosis, targeted screening, partner notification, and effective treatment have led to a slow decline in the incidence of genital chlamydial infection in countries where these programs have been implemented (13). The true rate of decline may be higher than the reported rate because of increased sensitivity of laboratory testing and more widespread screening. In women, screening of chlamydial infection at the time of Papanicolaou tests, prenatal visits, or attendance at family planning or pregnancy counseling clinics have been effective. In asymptomatic men, who are less likely to access care, asymptomatic infection is not adequately addressed by current public health programs.
In contrast to genital chlamydial infection, trachoma is a household disease that has disappeared in many parts of the world because of improved living conditions and hygiene. In trachoma-endemic areas, severe disease leading to scarring and blindness may be the result of frequent reinfection or persistent infection in those whose immune system does not mount an adequate response to clear the infection. For both ocular and genital chlamydial infections, recent advances in diagnostic and screening technology and single dose antimicrobial therapy will likely have a significant impact on the efficacy of disease control programs and the opportunity for eventual disease eradication.
Laboratory Diagnosis
Since curative antibiotic therapy for chlamydial infections is readily available
and inexpensive, early diagnosis is an essential component of public health programs to
control these infections. The goals of early identification are to interrupt the chain of transmission
in the community and to prevent long-term sequelae. Isolation of the organism in cell
culture had been the traditional method for laboratory diagnosis and has remained the method
of choice for medicolegal specimens because of its specificity. However, culture
requires expensive equipment, technical expertise, and stringent transport conditions to
preserve specimen viability; it also has a turnaround time of 2 to 3 days. Hence, in many
settings, culture has been replaced by antigen-detection methods, such as enzyme immunoassays
(EIA) and direct fluorescence assays (DFA), which have less demanding transport requirements
and can provide results on the same day. EIAs are suitable for public health laboratories
serving large geographic areas because specimens are stable in transport under ambient
conditions and are inexpensive because they allow specimens to be processed in batches by
automated equipment. Assays are typically based on the capture of the
A major advantage of the increased sensitivity of these molecular amplification tests is that noninvasive specimens, such as urine, can be used for testing. The ease of collection and the lack of sampling bias of urine specimens make screening feasible in settings outside physicians' offices. PCR assays on urethral or cervical swabs for the laboratory diagnosis of genital chlamydial infection in symptomatic men and women show sensitivities of 89% to 100% and specificities of 99% to 100% compared with the traditional culture or PCR test, confirmed by a second PCR reaction targeting a different gene (16-18). For urine specimens, PCR assays show sensitivities of 87% to 100% for men and 92% for women and specificities of 96% to 100% for men and 95% for women (18-20). In a study of 447 women with a prevalence of infection of 6%, the sensitivity of urine LCR was 96% compared with 56% for cervical swab culture, 78% for cervical swab EIA, and 37% for urine EIA (21). For men in the same study, the sensitivity of urine LCR was 96% compared with 68% for urine EIA, and 38% for urethral swab culture. In a multicenter study of 2,132 women, cervical swab LCR showed a sensitivity of 87% to 98% compared with a sensitivity of 52% to 92% for culture (22). In LCR studies, a true positive was defined as culture positive or LCR positive confirmed with DFA or another LCR assay with a different DNA target. Thus it appears that molecular amplification techniques for the detection of C. trachomatis in urine specimens from both men and women are a substantial improvement over conventional diagnostic and screening methods and will provide an important tool for decreasing the reservoir of infection, especially in asymptomatic men.
In the diagnostic laboratory, molecular techniques present different problems for specimen handling and interpretation of results than cell culture or antigen detection (15). Inherent in the increased sensitivity of these molecular techniques is the potential for false-positive results due to cross contamination between specimens, and run-to-run contamination from equipment, reagents, and supplies. These problems can be overcome by observing stringent rules for specimen preparation (e.g., dedicated equipment) and separating specimen processing and reagent preparation areas to prevent contamination. Enzymatic or photochemical sterilization can be used to eliminate run-to-run contamination. False-negative results may be due to substances in specimens inhibitory to enzymes used for amplification. Known inhibitors include phosphate ions, heparin, heme, crystals in the urine specimens, and detergents used in specimen processing. Internal controls are now commercially available to detect false negatives.
Although molecular tests are more expensive than EIA, cost-effectiveness studies
should take into consideration the benefits of averting the enormous costs of long-term
reproductive sequelae in women with undetected infections, adverse pregnancy outcomes, and
HIV infection. Targeted screening of women to detect cervical chlamydial infection decreases
the incidence
Treatment
Azithromycin prescribed as a single oral 1-g dose is equivalent to the traditional
7-day regimen of doxycycline for treating ocular and uncomplicated genital chlamydial
infections (26-28). Compared with conventional therapy, azithromycin has excellent
pharmacokinetic characteristics, such as increased bioavailability; lower incidence of gastrointestinal
tract side effects; and increased concentration in mucus, macrophages, and tissues with a half
life of 5 to 7 days (29). These characteristics allow for single dosing, which alleviates the
problem of patient noncompliance with multiday regimens. With single-dose therapy, the potential
for reinfection due to earlier resumption of sexual activity is a concern. At present, there
are limited data on the use of single-dose therapy in adolescents, during pregnancy, and
for syndromes such as PID, cervicitis, and nongonococcal urethritis (30-33). Studies are
needed to determine if these regimens achieve clinical and microbiologic cure while
preserving fertility and preventing further tissue damage to the upper genital tract.
Although the higher cost of azithromycin may be prohibitive for its use in resource-limited settings, selective use in persons at high risk or in those with a history of noncompliance may prove cost-effective. The cost of retreatment as a result of noncompliance and the additional cost of contact tracing can make single dose azithromycin more cost-effective than doxycycline (34).
Pathogenesis
Interesting findings in three areas of C.
trachomatis pathogenesis further delineate the complex bacteria-host relationship in disease and may have implications for vaccine
design. These new observations include the extensive but unexpected polymorphism of the
major outer membrane protein (MOMP), the evidence for genetic susceptibility to disease, and
the association of antibody response to the 60 kDa heat shock protein (CHSP60) with
the development of adverse sequelae following ocular and genital infections.
Polymorphism of MOMP
The ecologic success of a pathogen is determined in part by its ability to evade
host defenses. With C. trachomatis, MOMP is a major target for protective host immune
responses, such as neutralizing antibodies and possibly, protective T-cell responses (35,36). The basis
for MOMP antigenic variation is allelic polymorphism at the omp-1 locus, and immune
selection appears to be occurring in host populations frequently exposed to
C. trachomatis (37). Each variant apparently only infects hosts lacking serovar-specific immunity to that variant,
and the ecologic success of chlamydiae may be due to their ability, under immune
selection pressure, to generate successive allelic variants (36). DNA sequence analyses of isolates
from different populations show that most MOMP variants are results of single amino
acid substitutions (37-39). Recombination of sequences from MOMP during mixed infections
may also have occurred. Recombinant variants with mosaic sequences of MOMP from
different strains were especially frequent in persons with high rates of infection. MOMP variants
were also more frequently found in women with PID than in those with lower genital
tract infections, which suggests a relationship between sequence variation in MOMP and
more invasive disease (39). Clearly, the extensive polymorphism of MOMP, the tempo for
variation, and the mechanism of immune selection have
Genetic Susceptibility to Disease
HLA B27 has been associated with Reiter's syndrome following genital
chlamydial infection (40). Only a subset of infected persons appear to have long-term complications
after acute or repeated chlamydial infections. In a study of 306 persons from
trachoma-endemic communities in the Gambia, the HLA class I antigen HLA-A28 was significantly
more common in case-patients than in age-, sex-, and location-matched controls (41). In
particular, the A*6802 allele was overrepresented among case-patients. It may be that
immunopathology is associated with HLA-A*6802 restricted cytotoxic T-lymphocyte responses. The frequency
of HLA class II alleles was similar among cases and controls suggesting that, if class
II restricted T-cell responses are important in immunopathology, they were not targeted
at single epitopes. No individual HLA type was associated with protection from scarring,
which suggests that multiple or complex T-cell responses may be involved in protective
immunity. Susceptibility to chlamydial PID in a study of sex workers in Nairobi, Kenya, has
been associated with a HLA class I allele, HLA A-31 (42). Studies are needed to determine
whether susceptibility to silent PID, ectopic pregnancy, and progression to tubal factor infertility
are associated with HLA class I restricted immune responses.
Role of CHSP60 in Immunopathology
Antibody response to a 57 kDa chlamydial protein was initially observed more
frequently in women with tubal infertility than in controls (43). This protein was subsequently
identified as a heat shock protein of the GroEL family of stress proteins. The association
between antibody response to CHSP60 and PID, ectopic pregnancy, tubal infertility, and trachoma
(44-48) has been documented. The risk factors associated with CHSP60 antibody response
are similar to those for chlamydial PID and include older age and chronic or repeated
infections. There appears to be genetic restriction for the CHSP60 antibody response. In a study
of trachoma in the Gambia, HLA DRB1*0701 was positively correlated with CHSP60
response, while DRB1*0301 and DQB1*0501 were negatively associated (48). However, these
alleles were not associated with trachoma and may reflect linkage disequilibrium between HLA
class II alleles and polymorphic markers for other immune response genes.
At present, it remains unclear whether antibody to CHSP60 is causally involved in chlamydial immunopathogenesis or is merely a marker of persistent chlamydial infection (35). Both may be true. In cells persistently infected with C. trachomatis, the expression of CHSP60 is normal, while other antigens, such as MOMP, are downregulated, thus providing continued antigenic stimulation for the CHSP60 antibody response observed in persons with long-term sequelae (49). T-cell responses to chlamydial antigens, including CHSP60, were more depressed in persons with trachoma than in those who recovered from infection without sequelae (50). Persons with trachoma or reproductive sequelae have high levels of serum antibody response to C. trachomatis. In guinea pigs and in gene knock-out mice, both B- and T- cell responses have been important in immunity and resolution of infection (51,52). Therefore, persons with long-term sequelae may have predominantly Th2 responses, characterized by high levels of B-cell response and inadequate T-cell responses that may not clear the infection thus leading to chronic inflammation. Immunopathology may also be the result of a hit-and-run mechanism in which immune response to CHSP60 breaks self-tolerance to the human HSP60 and leads to an autoimmune reaction that results in tissue damage (35).
Reports of outbreaks of psittacosis in duck and turkey processing plants show that, in spite of availability of medicated feed, diagnostic testing, and screening of poultry, C. psittaci infections continue to be a public health concern (53,54). High rates of chlamydial infection in household cats and asymptomatic carriage of C. psittaci in cats from breeding catteries raise the possibility that human C. psittaci infection from pets other than birds may be underdiagnosed (6,7,55,56). Studies of animal and cellular tropism of various strains within the species may give important clues to the pathogenesis of C. psittaci infections.
Clinical Manifestations
Human infection caused by exposure to infected birds or poultry is manifested as a
flulike illness characterized by fever, chills, headache, and less frequently, cough, myalgias, rash,
arthralgia and joint swelling, and atypical pneumonia in more severe cases. The
incubation period is 6 to 19 days. Infections transmitted from ruminants are rare, but
placentitis, disseminated intravascular coagulation, and spontaneous abortion in women exposed
to infected sheep during lambing have been reported (56). Zoonoses associated with exposure
to ruminants are characterized by multiorgan involvement often resulting in hepatic and
renal dysfunction and endocarditis. Human conjunctivitis, glomerulonephritis, and
endocarditis caused by C. psittaci from infected cats and pigeons have been reported (55).
Diagnosis and Treatment
Serodiagnosis has been the method of choice for human
C. psittaci infections because culture is technically demanding and represents an important biohazard. The
complement fixation assay is genus specific. Its interpretations should depend on clinical symptoms
and patient history. The microimmunofluorescence (MIF) assay can detect species-specific IgM
or IgG antibodies. Antigen detection methods, such as EIA, have been used, but they are
based on the capture of the genus-specific LPS. PCR assays are not yet commercially available
but can offer lower detection limits of 10 EBs or less (57,58). Molecular techniques not
only provide more sensitive and rapid diagnosis than serology, but they also provide
the opportunity for fingerprinting strains. This is particularly useful in outbreak
investigations and for the confirmation of zoonotic transmission from infected birds or animals.
The recommended treatment for C. psittaci infection is 250 mg of tetracycline 4 times daily for 21 days. Although the death rate is low, prolonged hospitalization may be required. Protracted recovery and high incidence of relapse have also been noted.
Laboratory Diagnosis
Accurate and rapid laboratory diagnostic methods leading to improved patient
care, appropriate use of antimicrobial therapy, and better understanding of the epidemiology
of this emerging pathogen (59,60) are needed. Culture is highly specific but is
technically demanding often requiring multiple passages over a period of weeks to show a positive
result. C. pneumoniae has been isolated from the nasopharynx of healthy persons, but the rate
of asymptomatic carriage in a normal population is unknown (61).
Antigen detection tests, such as EIA and DFA, and molecular detection methods, such as PCR assays, provide a rapid diagnosis without stringent transport requirements. Monoclonal antibodies specific for C. pneumoniae are now commercially available for DFA and for culture confirmation (62). PCR assays have lower detection limits of 10 to 100 EBs (57,58,63-65). The protocol developed by Tong and Sillis amplifies a target sequence conserved between C. pneumoniae and C. psittaci and hence can detect DNA from either pathogen in a single assay (57). A nested PCR procedure is used to differentiate between the C. pneumoniae and C. psittaci amplicons. The protocol of Rasmussen et al. amplifies a genus-specific target, followed by species differentiation using restriction enzyme digestion (58). The development of multiplex PCR assays containing primers specific for a panel of respiratory pathogens will be useful.
The MIF assay is the standard method used for chlamydia serology today. Ekman compared the performance of the complement fixation (CF), LPS-based EIA, and MIF tests for the serodiagnosis of C. pneumoniae and C. psittaci infections in an elderly population and found that the CF test has a sensitivity of 10% compared with 88% and 72% for MIF and EIA, respectively (66). IgM antibodies were only detected in 11% of the cases. IgM antibodies are rarely produced in reinfections with C. pneumoniae. CF tests may be useful in early initial infections as LPS antibodies are produced early in infection. Serodiagnosis may be made by demonstrating a fourfold rise in CF or EIA titer in paired sera taken a week apart, compared with the 3 weeks or more that it takes by MIF to demonstrate seroconversion. Because reinfections are common and LPS-based serologic tests are not useful in reinfection, the MIF assay remains the most useful and specific tool for the serodiagnosis of respiratory infections due to C. pneumoniae.
Treatment
The newer macrolides, clarithromycin and azithromycin, with longer tissue half-life
and concentration in mucus and macrophages and improved bioavailability can
potentially provide shorter and better-tolerated regimens for the treatment of respiratory infections
due to C. pneumoniae than doxycycline or erythromycin, which have to be given for 2 to 3
weeks to avoid relapse. They may also be preferred for empiric therapy as they provide
broader coverage than erythromycin against etiologic agents in community-acquired pneumonia.
The optimal duration of treatment for respiratory infections due to
C. pneumoniae needs to be determined since studies with documented microbiologic cure are limited, and recurrence
of infection is common (67).
Association with Atherosclerosis
The association of C. pneumoniae infection with coronary heart disease and
acute myocardial infarction was first made on the basis of elevated IgG and IgA antibodies and
LPS containing immune complexes in 50% to 60% in patients with coronary heart disease or
acute myocardial infarction compared with 7% to 12% in the controls. This study did not take
into account risk factors for heart disease such as smoking, hypertension, or serum lipid
levels. Subsequently, several cross-sectional studies involving 46 to 461 study participants
have shown that a similar association of IgG antibodies against
C. pneumoniae with coronary artery disease and carotid disease with adjusted odds ratios of 1.6 to 2.6 after controlling
for known risk factors (68-72). Electron microscopy, PCR, and immunochemical evidence of
C. pneumoniae in coronary arterial fatty streaks and atheromatous plaques have also
been described (72,73).
Two more recent studies reported equivocal findings. In one, C. pneumoniae was detected in 79% of 90 coronary atherectomy specimens from symptomatic patients by direct immunofluorescence and was confirmed by electron microscopy. Only 4% of 24 control nonatherosclerotic coronary specimens were positive for C. pneumoniae (74). The 24 control samples included 12 from heart transplant patients whose arteries were damaged, but not by atherosclerosis. The absence of C. pneumoniae in these tissue samples argues against its role as a passenger recruited to the site of injury in macrophages. In the other study, C. pneumoniae was not detected in 58 coronary atheroma specimens by culture, PCR, or electron microscopy (75). The seroprevalence of C. pneumoniae in 65 case-patients was not different from that in 28 asymptomatic controls. In fact, IgG titers were higher in controls than in case-patients. Nonetheless, data suggest that the association of C. pneumoniae with atherosclerosis is consistent and biologically plausible. Whether C. pneumoniae is causally involved or is a bystander trapped in the atherogenic process is unclear.
The sustained IgA and IgG antibody levels against C. pneumoniae in persons with atherosclerosis suggest that chronic infection may be frequent after infection. The site of colonization for a chronic C. pneumoniae infection may be in the alveolar macrophages of the lung. Thus the initial event in atherogenesis may be the formation of the fatty streak. Fatty streaks consist of lipid-laden macrophages derived from blood monocytes and T lymphocytes attracted to the arterial subintima. Conversion of the fatty streak to atheroma depends on many factors, e.g., the proliferation and differentiation of smooth muscle cells and fibroblasts. Chronic infection with C. pneumoniae may result from organisms harbored in macrophages trapped in the arterial wall. Growth of C. pneumoniae in endothelial, smooth muscle cells, and macrophages from peripheral blood monocytes has been reported (76). Injured blood vessels initiate events that promote thrombosis and platelet adhesion at the site of injury. These events in turn promote atherosclerosis. Tissue injury through C. pneumoniae-specific circulating immune complexes in patients with chronic heart disease may be an alternate mechanism or compounding atherogenesis. The idea that an infectious agent is involved in the atherogenic process is not new, but the role of C. pneumoniae in this process needs to be defined.
Association with Asthma
The prevalence of asthma, an important chronic respiratory disorder, has been
steadily increasing. Viral and Mycoplasma
pneumoniae infections have been implicated in exacerbating the disease. The first observations on the association of
C. pneumoniae infection with the exacerbation of asthma were made in 1986 when wheezing was associated with
acute bronchitis due to pneumoniae infection (8,77). Subsequent studies showed that
exacerbation of asthma due to C. pneumoniae infection may occur in 1% to 11% of respiratory infections
in adults as well as children. The mechanism underlying the association is unclear.
Preliminary results in animal models suggest that
C. pneumoniae can produce persistent infection
and cause pulmonary inflammation, and production of chlamydia-specific IgE antibodies
in children with reactive airway disease has been demonstrated (78). A possible scenario for
this association is an antigen-specific allergic reaction with the release of
pulmonary inflammatory mediators and recruitment of inflammatory cells to the airways,
causing airway epithelial damage. Activated T lymphocytes and cytokines appear to play a
critical role as mediators of persistent inflammation in asthma. IL-4 is essential for B
lymphocytes class switching from IgG to IgE. In vitro human IgE synthesis is reciprocally regulated by
IL-4 and interferon-gamma. Thus cytokines from a
Th2 response to infection would facilitate and promote IgE production. Immunotherapy or glucocorticoid therapy targeting
CD4+ T cells may decrease the proinflammatory role of these cells and alleviate symptoms of asthma. The
role of persistent infection in the pathogenesis of asthma merits further study because,
unlike
The hallmark of chlamydial infection is that most persons infected have mild to no apparent clinical disease and some have severe disease. Asymptomatic infection not only creates a problem in detecting cases for disease control programs but also contributes to the development of long-term adverse sequelae, such as scarring trachoma from ocular C. trachomatis infection, pelvic inflammatory disease, ectopic pregnancy, and tubal factor infertility from genital C. trachomatis infection. The recent availability of effective single dose oral antimicrobial therapy and sensitive molecular amplification tests that allow the use of noninvasive specimens for diagnosis and screening is expected to have a major impact in reducing the prevalence of disease in the next decade. New information from cell biology as well as data from observing the interaction of chlamydiae with the host in terms of metabolic requirements and immune evasion strategies offer clues about the pathogenesis of chlamydia infections and may eventually lead to an effective vaccine. Sporadic outbreaks of psittacosis continue to be reported despite the use of medicated feed and the screening of poultry. Recent reports of C. psittaci in cats from breeding catteries illustrate the potential of zoonotic diseases transmissible to humans from pets other than birds. Two new species of chlamydiae, C. pneumoniae and C. pecorum, were desig-nated in 1989 and 1992, respectively. Clinical manifestations associated with C. pneumoniae infection continue to emerge. Possible links to chronic conditions, such as atherosclerosis and asthma remain to be elucidated. With the recent discovery of the involvement of infectious agents in other chronic conditions, it seems reasonable to apply molecular tools for chlamydial detection to identify their potential involvement in other etiologically undefined chronic inflammatory conditions such as inflammatory bowel disease and rheumatoid arthritis.
Dr. Peeling is a research scientist and chief of the Division of Chlamydial and Mycoplasma
Diseases at the Laboratory Centre for Disease Control, Health Canada. She is interested in the diagnosis
and pathogenesis of chlamydial infections with particular emphasis on the development, risk
assessment, and possible prevention of adverse ocular and reproductive sequelae in human chlamydial infections.
Dr. Brunham is professor and head of the Department of Medical Microbiology at the University of Manitoba. He has a long standing interest in the immunology of chlamydial infections, and his current research focus is on vaccine development. |
Address for correspondence: Rosanna W. Peeling, LCDC Chlamydia Laboratory, Health Sciences Centre MS 673C, 820 Sherbrook St., Winnipeg, Manitoba, Canada R3A 1R9; fax: 204-787-4699; e-mail: rosanna_peeling@isdtcp3.hwc.ca.
References